Last Updated : April 22, 2024
Details
Generic Name:
avapritinib
Project Status:
Received
Therapeutic Area:
Advanced Systemic Mastocytosis
Manufacturer:
Medison Pharma Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0335-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Anticipated: for the treatment of adult patients with Advanced Systemic Mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Anticipated: for the treatment of adult patients with Advanced Systemic Mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | March 12, 2024 |
|---|---|
| Call for patient/clinician input closed | May 07, 2024 |
| Submission received | April 19, 2024 |
| Submission accepted | - |
Last Updated : April 22, 2024